To read the full story, subscribe or sign in.

Despite favorable comparison to U.S., healthcare in Canada heads for reckoning

Feb. 5, 2014

By David Godkin

No Comments

BioWorld MedTech

Today's news in brief

BioWorld

BioWorld briefs for Dec. 4, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 4, 2024.

Illustration of man holding magnifying glass to human body model showing muscle anatomy

In muscular dystrophies, gene therapies race the clock

BioWorld

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...

AI-generated illustration of heart and metabolic impact

Bridgebio, with FDA approval, faces Pfizer in ATTR

BioWorld

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...

Phase III AMD miss leaves BLA Outlook same with bevacizumab

BioWorld

Outlook Therapeutics Inc. is forging onward with plans to resubmit the BLA for ONS-5010, an ophthalmic version of Avastin (bevacizumab, Roche AG), after a missed...

Upgrade your daily dose of biopharma and medtech news

Despite favorable comparison to U.S., healthcare in Canada heads for reckoning